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Abstract.
Background: Frontotemporal lobar degeneration (FTLD) is a progressive dementia characterized by focal atrophy
of frontal and/or temporal lobes caused by mutations in the gene coding for sequestosome 1 (SQSTM1), among
other genes. Rare SQSTM1 gene mutations have been associated with Paget’s disease of bone, amyotrophic lateral
sclerosis, and, more recently, frontotemporal lobar degeneration (FTLD).
Objective: The aim of the study was to determine whether a characteristic pattern of grey and white matter loss
is associated with SQSTM1 dysfunction.
Methods: We performed a voxel-based morphometry (VBM) study in FTD subjects carrying SQSTM1 pathogenic
variants (FTD/SQSTM1 mutation carriers; n = 10), compared with FTD subjects not carrying SQSTM1 mutations
(Sporadic FTD; n = 20) and healthy controls with no SQSTM1 mutations (HC/SQSTM1 noncarriers; n = 20). The
groups were matched according to current age, disease duration, and gender.
Results: After comparing FTD/SQSTM1 carriers with Sporadic FTD, a predominantly right cortical atrophy pattern
was localized in the inferior frontal, medial orbitofrontal, precentral gyri, and the anterior insula. White matter
atrophy was found in both medial and inferior frontal gyri, pallidum, and putamen.FTD/SQSTM1 carriers compared
with HC/SQSTM1 noncarriers showed atrophy at frontal, temporal, and parietal lobes of both hemispheres whereas
the MRI pattern found in Sporadic FTD compared with controls was frontal and left temporal lobe atrophy,
extending toward parietal and occipital lobes of both hemispheres.
Conclusions: These results suggest that fronto-orbito-insular regions including corticospinal projections as
described in ALS are probably more susceptible to the damaging effect of SQSTM1 mutations delineating
a specific gene-linked atrophy pattern.
Keywords: Dementia, frontotemporal dementia, SQSTM1 protein, voxel-based morphometry
INTRODUCTION
Frontotemporal lobar degeneration (FTLD) is a
progressive dementia characterized by atrophy of
frontal and/or temporal lobes resulting from different
pathological processes, frequently linked to genetic
mutations. FTLD is associated (15%) with motor neu-
ron disease (MND) or amyotrophic lateral sclerosis
(ALS). A frequent cause of FTLD+/-MND is a G4C2
repeat expansion in the chromosome 9 open reading
frame 72 gene (C9ORF72; OMIM#: 614260). Less
frequently, FTLD is caused by mutations in other
genes such as the microtubule-associated protein
tau gene (MAPT; OMIM#: 157140) [1], progran-
ulin (GRN; OMIM#: 138945) [2], valosin containing
protein (VCP; OMIM#: 601023), fused in sarcoma
(FUS; OMIM#: 137070), TAr DNA-binding pro-
tein (TARDBP; OMIM#: 605078) gene, and, very
recently, in the gene coding for sequestosome 1
(SQSTM1; OMIM#: 601530), which causes Paget
disease of bone [3, 4, 5, 6, 7].
The SQSTM1 gene is located in chromosome 5
and encodes for p62, a ubiquitin binding protein
involved in protein phosphorylation and degrada-
tion, autophagosome formation, mediation of the
NFkappaB activation pathway, and osteoclast growth
factor regulation [8]. There are seven mutational stud-
ies reporting rare SQSTM1 variants associated with
FTLD or ALS, suggesting that SQSTM1 has a sig-
nificant role in both diseases [9, 10]. Since there
is no information on the regional brain effects of
SQSTM1 variants in the literature, we hypothesized
that VBM-studies in SQSTM1-carriers patients with
FTLD can be useful for two reasons: first, in order to
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determine whether SQSTM1mutations are associated
with specific clinical FTLD phenotypes and sec-
ondly to identify whether the expression of SQSTM1
mutations in the brain have any significant regional
differences when compared with non-carriers, thus
reflecting an increased regional susceptibility.
MATERIALS AND METHODS
Subject selection and comparison groups
This is a multicenter retrospective and exploratory
collaborative study in which all the members of the
EU EOD consortium [10] and other authors of pub-
lished studies analyzing the SQSTM1 gene [10, 11]
were asked to provide available brain MRI scans from
the subjects screened in previous studies whether they
were FTD/SQSTM1 carriers or not. A subject was
considered to be a FTD/SQSTM1carrier when she/he
fulfilled research criteria for FTLD [12] and carried
a disease-segregating SQSTM1 genetic variant or, if
DNA samples from relatives to demonstrate familial
segregation were unavailable, their SQSTM1 variant,
was only found in FTLD cases or the variants were
more frequent among the cases [9, 11].
The T1-weighted images were obtained from five
European research centers: the Center for Aging
Brain and Neurodegenerative Disorders. Neurology
Unit, University of Brescia, Brescia, Italy; Univer-
sity of Turin, Department of Neuroscience “Rita Levi
Montalcini” Studi di Torino, Turin, Italy; Center de
Recherche de I’ Institut du Cerveau et de la Moelle
Epinie`re, Hoˆpital de la Pitie´-Salpeˆtrie`re - France;
Centro Hospitalar e Universita´rio de Coimbra, Coim-
bra, Portugal and the Clı´nica Universidad de Navarra,
Pamplona, Spain (Table 1). Seven MRI scans from
the Sporadic FTD subjects were discarded because
of poor image quality or movement artifacts. On
the other hand, two FTD/SQSTM1 carrier patients
were discarded, one because the images were not
isotropic and another one because the patient carried
two heterozygous FTLD-causing mutations: p.P392L
SQSTM1 and the C9orf72 expansion.
Once we obtained the MRI scans, the group of
FTD/SQSTM1 carrier subjects was double-matched
with a group of Sporadic FTD/SQSTM1 subjects and
a group of cognitively intact SQSTM1 noncarriers.
The matching process was performed in order to have
similar gender, age at onset, disease duration, and
age at evaluation across groups (Table 2). Finally,
except for a patient with semantic dementia, the FTD
patients were matched across groups by their clini-
cal FTD presentation. Sporadic FTD subjects did not
carry mutations in the GRN, MAPT, or C9ORF72
genes.
Demographic and clinical data and analysis
Normality and variance homogeneity for the
variables age at evaluation, Mini-Mental State Exam-
ination (MMSE), disease duration, and age at onset
were included in the study and tested using the
Shapiro-Wilk and Levene tests, respectively. Anal-
ysis of variance was applied to test the differences
between the means of age at evaluation and MMSE
variables among the three study groups. When only
the two groups (FTD/SQSTM1 carriers and Sporadic
FTD) were compared, a t-test was applied to evalu-
ate age at onset and disease duration. FTD subtype
and family history variables were compared using
the exact χ2-test. The analysis was carried out using
the program SPSS 15.0 software for Windows (SPSS
Inc., Chicago, Illinois, USA). Bonferroni’s correc-
tion was applied for multiple comparisons in all tests
performed (Table 2).
Table 1
Number of participants in each group for center
Centers FTD/SQSTM1 Sporadic HC/SQSTM1
carriers FTD noncarriers
Number of participants
Centre for Aging Brain and Neurodegenerative Disorders. Neurology
Unit, University of Brescia, Brescia, Italy
2 8 0
University of Turin, Department of Neuroscience “Rita Levi
Montalcini” degli Studi di Torino, Turin, Italy
2 5 0
Centre de Recherche de I’ Institut du Cerveau et de la Moelle Epinie`re,
Hoˆpital de la Pitie´-Salpeˆtrie`re - France
0 5 0
Centro Hospitalar e Universita´rio de Coimbra, Coimbra, Portugal 3 0 0
Clı´nica Universidad de Navarra, School of Medicine in the Memory
Disorders Unit, Department of Neurology, Pamplona, Spain
1 14 20
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Fig. 1. Analysis displaying grey matter loss on the rendered surface of the brain in the following contrasts: A) Contrast FTD/SQSTM1
carriers versus Sporadic FTD (Threshold p < 0.05. FWE cluster-wise p < 0.01); B) FTD/SQSTM1 carriers versus HC/SQSTM1 noncarriers;
and C) Sporadic FTD versus HC/SQSTM1 noncarriers (Threshold p < 0.05. FWE cluster-wise p < 0.001).
Neuroimaging assessment
Data acquisition
The T1-weighted images obtained from five cen-
ters used five different 1.5 T scanners. Three
FTD/SQSTM1 carriers underwent their MRI scan in
1.5 T GE Medical Systems scanner at two different
centers, 5 FTD/SQSTM1 carriers in 1.5-T Siemens
Symphony scanner at two different centers, and 2 in
1.5-T Philips Medical Systems at only one center. The
MRI scans from Sporadic FTD and 20 HC/SQSTM1
subjects were acquired in 1.5-T Siemens Symphony
scanners at two different centers. All T1-weighted
images had a voxel size of 1 × 1 × 1 mm.
MRI pre-processing
Determination of image quality followed the local
internal protocol consisting of examination of the
voxel size, the isotropic characteristic of the images
and the movement artifacts. Secondly, after the pre-
processing, we performed a covariance matrix that
showed the covariance between volumes in each
subject. These covariance values (Supplementary
Figure 1) demonstrated the homogeneity of the
sample.
We used the Statistical Parametric Mapping
8 software (SPM8; Wellcome Trust Centre for
Neuroimaging; University College London, UK)
implemented in Matlab 7.1 environment (Math-
Works, Inc.) for image preprocessing. All images
were transformed from the standard DICOM format
(Digital Imaging and Communication in Medicine)
to the NIfTI format (Neuroimaging Informatics Tech-
nology Initiative); the MNI localization of each image
was manually rectified using the anterior and pos-
terior commissures and anatomical references. First,
we generated a custom template using the Diffeomor-
phic Anatomical Registration with the Exponentiated
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Lie Algebra algorithm tool (DARTEL) [13]. Subse-
quently, the images were processed using the New
Segment tool for defining tissue probability maps
through non-linear deformation and registration, in
order to obtain grey matter (GM), white matter (WM)
and cerebrospinal fluid images [13]. These individual
GM and WM images were spatially normalized with
the DARTEL- custom template made with the images
of the population tested in this study. In this image
processing method, we multiplied each GM and WM
image spatially normalized by its total intracranial
volume before and after normalization (modulation
step). Finally, they were smoothed with a full-width-
half-max (FWHM) 8-mm Gaussian kernel to increase
the variation signal in the anatomical structure.
Statistical group analysis
Segmented images from FTD/SQSTM1 carriers,
Sporadic FTD and HC/SQSTM1 noncarriers were
compared in a voxel-wise manner by performing
two ANOVA analyses (one for GM and another for
WM): these ANOVAs included a ‘group’ factor with
three levels (FTD/SQSTM1 carriers, Sporadic FTD
and HC/SQSTM1 noncarriers). Since the subjects
were age- and gender-matched, the scanner type was
included as covariate with the goal of eliminating
its possible effect on the results. After determining a
significant mean effect of the group factor, the follow-
ing pair-wise SPM-t comparisons were carried out:
FTD/SQSTM1 carriers versus Sporadic FTD non-
carriers, FTD/SQSTM1 carriers versus HC/SQSTM1
noncarriers, and Sporadic FTD versus HC/SQSTM1
noncarriers.
The statistical significance of the contrasts of
FTD/SQSTM1 carriers versus HC/SQSTM1 non-
carriers and Sporadic FTD versus HC/SQSTM1
noncarriers was set up with a primary threshold of
voxel-wise p = 0.001, which yielded a cluster-extent
based threshold of k = 41976 and 2018 in GM (t = 3.2)
and k 1022 and 825 in WM (t = 3.2), respectively.
For the contrast of FTD/SQSTM1 carriers versus
Sporadic FTD noncarriers, a primary threshold of
voxel-wise p < 0.01 was set up due to low statistical
power, which yielded a cluster-extent based thresh-
olding of k = 6124 in GM (t = 2.4) and 5590 in WM
(t = 2.4). Finally, the threshold for the resulting clus-
ters in each contrast was limited p < 0.05 family-wise
error (FWE) correction. The cluster-extent based
thresholding was calculated with the Gaussian ran-
dom field (GRF) in Statistical Parametric Mapping
(SPM8) using the estimated intrinsic smoothness
based on residual images. Tables were created using
the SPM8 Anatomy toolbox version 1.5 [14], and
anatomical areas reported were based on its V20 maps
for GM. For WM evaluation we used a tractography-
based atlas of human brain connections from the
Natbrainlab website (http://www.natbrainlab.com/).
RESULTS
Subjects available for the VBM analysis
In this study, ten FTD/SQSTM1 carriers (median
age = 70.1; range = 52-81; 50% male) were com-
pared with twenty Sporadic FTD (median age = 70.6;
range = 54-82; 50% male) and twenty HC/SQSTM1
noncarriers (median age = 70.0; range = 54-80; 50%
male) (Table 2). All groups were matched by gen-
der, age at evaluation, and disease duration among
patients. The FTD/SQSTM1 carrier group included
two subjects with the SQSTM1 p.L238del vari-
ant and the other subjects carried one of the
following SQSTM1 variants: p.P392L, p.P387L,
pA33, E319K, P348L, P439L, T430P, and p.D329G
(Table 1). With regard to the clinical subtypes of
the FTD/SQSTM1 carriers, seven patients were diag-
nosed with behavioral FTD subtype (bvFTD) and
three with progressive non-fluent aphasia (PNFA).
In addition, one patient also had ALS, one Paget’s
disease, two presented parkinsonian signs and one
psychotic symptoms. Among the Sporadic FTD,
twelve patients had the bvFTD subtype, seven PNFA,
and one semantic dementia (SD).
Demographic and clinical analyses
There were no significant differences in age at eval-
uation across the groups (F = 0.02, p = 0.9). There
were no differences between FTD/SQSTM1 carriers
and Sporadic FTD in the other demographic variables
such as the age at onset (t = –0.3, p = 0.7), disease
duration (t = 0.5, p = 0.6), and FTD clinical subtype
(χ2 = 0.65, p = 0.72). We found significant differ-
ences in MMSE (group factor F = 18.1, p < 0.0001)
in FTD/SQSTM1 carriers versus HC/SQSTM1 non-
carriers (p < 0.0001) and Sporadic FTD versus
HC/SQSTM1 noncarriers comparisons (p < 0.0001).
There were no MMSE score differences between
FTD/SQSTM1 carriers and Sporadic FTD (p = 0.5).
Finally, differences were also found in the fre-
quency of family history of FTD and/or ALS, which
was higher in the FTD/SQSTM1 carriers (χ2 = 1414,
p = 0.003) (Table 2).
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Table 3
Volumetric grey matter loss contrast between FTD/SQSTM1 carriers versus Sporadic FTD
Side Area BA k p-value t x y Z
R Inferior Frontal Gyrus p. Triangularis 45 6124 0.01 3.78 42 11 24
R Inferior Frontal Gyrus p. Opercularis 44 3.74 41 11 22
44 3.17 53 11 12
R Inferior Frontal Gyrus p. Orbitalis 44 3.27 45 41 –3
R Precentral Gyrus 6 3.20 45 –2 45
3.00 33 –1 48
R Middle Frontal Gyrus 8 3.46 38 14 42
3.37 35 23 37
R Middle Orbital Gyrus 10, 11, 46 3.32 35 53 –3
R Insula Lobe 44 3.37 41 12 3
Statistically significant white matter loss; Side: laterality; BA: Brodmann Areas; k: number of voxels per cluster. p < 0.05 FWE cluster-wise
corrected p = 0.01; t: T-test score; x.y.z : MNI coordinates.
A
B
C
t
6
3
0
Fig. 2. Analysis displaying white matter loss on the rendered surface of the brain in the following contrasts: A) Contrast FTD/SQSTM1
carriers versus Sporadic FTD (Threshold p < 0.05. FWE cluster-wise p < 0.01); B) FTD/SQSTM1 carriers versus HC/SQSTM1 noncarriers;
and C) Sporadic FTD versus HC/SQSTM1 noncarriers (Threshold p < 0.05. FWE cluster-wise p < 0.001).
Grey matter VBM analysis
ANOVA analyses of GM data showed a signif-
icant main effect of the Group factor (F = 8.057,
p < 0.0001).
Comparison between FTD/SQSTM1 carriers
versus Sporadic FTD groups
On a direct comparison, the FTD/SQSTM1
carriers had smaller GM volumes than the Sporadic
FTD/SQSTM1 predominantly in the right hemi-
sphere, including inferior and middle frontal gyrus,
middle orbital gyrus, insula, and precentral gyrus
(Fig. 1A, Table 3, and Supplementary Table 1).
These results reflected a grey matter loss pattern
among the FTD/SQSTM1 carriers with impairment
of right prefrontal-orbital-insular regions with
relative preservation of the temporal lobes. In short,
FTD/SQSTM1 carriers’ atrophy pattern was specific
to the prefrontal cortex, involving premotor and
primary motor regions (Fig. 1 and Table 3). The
prefrontal right atrophic clusters were extended
bilaterally when this same contrast was thresholded
to t = 2.4, p < 0.01 uncorrected (Supplementary
Figure 2).
Comparison between FTD/SQSTM1 carriers
versus HC/SQSTM1 noncarriers
The 10 FTD/SQSTM1 carriers were compared with
20 HC/SQSTM1 noncarriers and showed severe GM
volume loss (p < 0.05 FWE cluster-wise corrected) in
the following regions: insula, inferior temporal gyrus,
precuneus, and inferior frontal gyrus of both hemi-
spheres, plus the right temporal lobe and cuneus and
middle orbital gyrus of the left hemisphere (Fig. 1B,
Supplementary Table 1).
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Comparison between Sporadic FTD versus
HC/SQSTM1 noncarriers
We observed widespread GM loss in the 20
Sporadic FTD compared with the 20 HC/SQSTM1
noncarriers (p < 0.05 FWE cluster-wise corrected)
with a predominant distribution in temporal and
frontal lobes. This pattern was consistent with the
results of previous VBM studies performed in FTLD-
control series where the underlying genetic causes
were not known [15]. The temporal atrophic clusters
were located in the left middle temporal gyrus, tem-
poral pole and superior temporal gyrus and in frontal
regions. The brain atrophy was specifically intense
at the insula and inferior and middle orbital gyrus
(Fig. 1C and Supplementary Table 2).
White matter VBM analysis
ANOVA analyses of WM data showed a signif-
icant main effect of the Group factor (F = 8.057,
p < 0.0001).
Comparison between FTD/SQSTM1 carriers
versus Sporadic FTD/ SQSTM1
The contrast between WM brain volume FTD/
SQSTM1 carriers versus Sporadic FTD/ SQSTM1
resulted in significant differences in regions under-
lying both medial and left inferior frontal gyrus,
triangular area, and in neighboring regions to left
pallidum globe and putamen (Fig. 2A and Supple-
mentary Table 3).
Comparison between FTD/SQSTM1 carriers
versus HC/SQSTM1 noncarriers
This contrast showed WM volume loss (p < 0.05
FWE cluster-wise corrected) in underlying regions
to the inferior frontal gyrus, primary motor cortex,
precuneus, superior occipital gyrus and particularly
along the borders of the insula, amygdala, and hip-
pocampus (Fig. 2B and Supplementary Table 4).
Comparison between Sporadic FTD versus
HC/SQSTM1 noncarriers
Finally, Sporadic FTD versus HC/SQSTM1
noncarriers contrast (p < 0.05 FWE cluster-wise
corrected) showed an atrophy pattern in cortico-
ponto-cerebellar regions such as the superior and
inferior cerebellar peduncles. We also found WM vol-
ume loss in occipital and frontal regions, the middle
temporal lobe and hippocampus (Fig. 2C and Sup-
plementary Table 5).
DISCUSSION
The present study is the result of a multicenter
collaborative effort provided by the EU EOD con-
sortium [10] where members were invited along with
researchers involved in the other studies that have
screened the SQSTM1 gene in FTLD subjects [10,
16] to collect available brain MRI scans from subjects
with and without SQSTM1 mutations. The aim of our
study was to analyze whether SQSTM1 pathogenic
variants lead to a specific regional neurodegenera-
tive pattern. For this purpose we used VBM MRI,
which we have used successfully in the past to iden-
tify regional brain atrophy associated with other
genetic variants, even in relatively small samples [17,
18]. In these studies, we reported that morphomet-
ric neuroimaging studies could identify brain regions
sensitive to the damaging effects of specific genetic
variants [15, 17, 18, 19].
In the present study, we found brain volume dif-
ferences between FTD/SQSTM1 carriers versus Spo-
radic FTD, where the GM loss in FTD/SQSTM1 car-
rier group followed an asymmetric right pattern, with
involvement of fronto-orbital regions, right inferior
frontal gyrus (pars triangularis, pars opercularis and
pars orbitalis), insula lobe, premotor and motor areas
(Fig. 1 and Table 3). The right inferior frontal gyrus
has been associated with cognitive emotion regula-
tion and executive functions, especially for salience
of external clues, regardless of whether that detection
is followed by the inhibition of a motor response,
the generation of a motor response, or no external
response at all [20]. The right anterior insula belongs
to the ventral attention system with connectivity
with frontal lobe regions implicated in goal-directed
behavior [21, 22]. On the other hand, the premo-
tor cortex is involved in visuomotor transformation
tasks, spatial orientation, learning, and cognitive
functions [23, 24]. The pattern of atrophy found in
FTD/SQSTM1 carriers involved the impairment not
only of the precentral cortex and corticospinal tracks
but also premotor and prefrontal cortex, which are
also impaired in human motorneuron disease [25].
Mutations in SQSTM1 gene were first described
to cause Paget’s disease [7] and years later familial
ALS [9]. In fact, the substantial loss of brain volume
in pre-motor cortical areas and in the cortico-spinal
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tract observed in our FTD/SQSTM1 carriers group
was not found in the Sporadic FTD when compared
to the control group. We suggest that this pattern
can be due to a subclinical impairment of the pre-
motor cortical areas and the cortico-spinal tract in
the FTD/SQSTM1 carriers group, since SQSTM1 is
also a disease-causing ALS gene. In a VBM study
of ALS with behavioral symptoms [26], the ALS
patients with apathy, depression, and anxiety showed
an atrophy profile very similar to that found in the
present study after comparing the FTD/SQSTM1 car-
riers with Sporadic FTD, comprising premotor and
motor areas and corticospinal tracts. These results
reinforce the idea that there could be an important
association between mutations in the SQSTM1 gene
and the FTD-MND spectrum [9–11]. We want to
highlight the point that our study collected brain MRI
scans from FTD subjects with different mutations in
diverse SQSTM1 gene domains that can result in vari-
able structural and functional abnormalities of the
protein leading to different disease phenotypes [10]
and, subsequently, to specific patterns of brain atro-
phy. However, since mutations in SQSTM1 gene are
so rare, it was not possible to assess the individual
morphological brain effect for each of the SQSTM1
variants.
To the best of our knowledge, there are no VBM
studies in patients with FTD and SQSTM1 mutations,
though one preliminary study measuring gray mat-
ter density in twelve patients with Paget’s disease of
bone and SQSTM1 mutations without FTD described
a predominantly left frontotemporal atrophy pattern
among patients [27].
Among the previous literature on VMB MRI anal-
ysis in other FTLD mutated genes [28, 29], Rohrer
et al. [29] performed a VMB MRI analysis of MAPT
and GRN mutations in FTLD carriers compared with
healthy controls and found among GRN mutation car-
riers a brain atrophy pattern with areas in common
with that which we identified in our study, which
included the orbitofrontal cortex and ventral insula,
with marked extra atrophy of the anterior and medial
temporal lobes and cingular cortex with a strong
asymmetric pattern. However, we have to consider
that they used a different methodology that enhances
the GM loss. By contrary, the VBM pattern found
among MAPT carriers was predominantly tempo-
ral and symmetrical. On the other hand, our VBM
atrophy pattern (FTD/SQSTM1 carriers versus Spo-
radic FTD) was quite different from the one found
in another VBM study of FTLD GRN carriers com-
pared to healthy controls, which showed greater loss
in posterior temporal and parietal lobes in this group
[27].
These authors performed an MRI analysis of three
groups of subjects with GRN and MAPT mutations as
well as C9ORF72 expansion carriers [30] describing
prominent atrophy of the anteromedial temporal
lobes in the MAPT group, in the inferior temporal
and parietal lobes in the GRN group, and in posterior
cerebral regions including the cerebellum in the
C9ORF72 group. Interestingly, the brain atrophy
pattern described for the Sporadic FTD group
(35% of them diagnosed with FTD-ALS) was more
consistent with the atrophy pattern that we found
in the FTD/SQSTM1 carriers versus Sporadic FTD
comparison.
In another VBM MRI study comparing C9ORF72
expansion carriers and noncarriers, a thalamic
atrophy and cerebellar volume loss in C9ORF72
expansion carriers was found [31]. In fact, the brain
atrophy profile was completely different from the one
found in our FTLD SQSTM1 carriers’ group which
encompassed the inferior frontal-orbital regions,
right IFG: pars triangularis, pars opercularis and pars
orbitalis, insula lobe, premotor, and motor areas.
These results can be influenced by a higher frequency
of the PNFA subtype in our patients’ group.
All the data derived from the VBM MRI studies in
subjects with FTD-causing mutations highlight the
fact that brain atrophy patterns can diverge accord-
ing to the mutated gene, probably as a result of
differences in mRNA expression and/or differential
regional brain susceptibilities.
Although, we have previously identified patterns
of regional brain atrophy associated with other
genetic variants with similar study designs to the
present one [15, 17, 18], our study still has several
limitations: the number of subjects is low, but
this was expected considering the low frequency
of SQSTM1 mutations among FTD patients. In
addition, the distribution of the three populations
studied (FTD/SQSTM1 carriers, Sporadic FTD and
HC/SQSTM1 noncarriers) was not homogeneous
among centers. This methodological imbalance, in
spite of the common quality control, can introduce a
bias, which was perhaps not totally corrected when
introduced as a covariate in the analyses.
CONCLUSIONS
In summary, our results reflect that FTD/SQSTM1
carriers show a right atrophy pattern in prefrontal-
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orbital-insular regions with relative preservation of
the temporal lobes different from that observed in
Sporadic FTD. The WM atrophy was present in
regions underlying the right medial frontal gyrus and
left medial and inferior frontal gyrus and close to
the left pallidum and putamen. However, our study
is retrospective and exploratory and has a number of
limitations (small sample size, multicenter study with
different MRI scanners, and absence of DTI data). To
better define the specificity of these patterns, larger
cross-sectional and longitudinal imaging studies will
be needed.
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